Codex DNA, Inc. (DNAY): Price and Financial Metrics

Codex DNA, Inc. (DNAY): $1.92

-0.37 (-16.16%)

POWR Rating

Component Grades













DNAY Stock Price Chart Interactive Chart >

Price chart for DNAY

DNAY Price/Volume Stats

Current price $1.92 52-week high $25.70
Prev. close $2.29 52-week low $1.87
Day low $1.91 Volume 783,822
Day high $2.32 Avg. volume 444,459
50-day MA $3.59 Dividend yield N/A
200-day MA $7.30 Market Cap 56.44M

Codex DNA, Inc. (DNAY) Company Bio

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

DNAY Latest News Stream

Event/Time News Detail
Loading, please wait...

DNAY Latest Social Stream

Loading social stream, please wait...

View Full DNAY Social Stream

Latest DNAY News From Around the Web

Below are the latest news stories about Codex DNA Inc that investors may wish to consider to help them evaluate DNAY as an investment opportunity.

Codex DNA to Present at the Cowen 42nd Annual Healthcare Conference

SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will present virtually at the 42nd Annual Cowen Healthcare Conference on Wednesday, March 9th at 2:10 pm Eastern time / 11:10 am Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel’ on Monday, March 7th at 10:30 am Eastern time / 7:3

Yahoo | February 24, 2022

Codex DNA (DNAY) Investor Presentation - Slideshow

The following slide deck was published by Codex DNA, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | February 17, 2022

Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN DIEGO, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that members of its management team will be participating in the SVB Leerink 11 th Annual Global Healthcare Conference. An updated version of Codex DNA’s corporate presentation will be available on Wednesday, February 16 th at 12:00 pm Eastern time / 9:00 am Pacific time.

GlobeNewswire | February 9, 2022

Despite 22% gain today, Codex DNA still well down from June IPO price

Despite double-digit gains today, Codex DNA (DNAY +22.7%) is still down ~38% from its IPO in June 2021. Its IPO was priced at $16. In afternoon trading today, shares stood at $9.33 Since the IPO, trading in Codex DNA has been volatile. Last month, Codex benefitted from a deal with...

Seeking Alpha | February 7, 2022

Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Proprietary short oligo ligation assembly (SOLA) technology used to enzymatically synthesize DNA fragments for the construction of full-length H1 and N1 genes from influenza A virusInitial performance results show potentially significant quality, time, and cost advantages compared to traditional chemical synthesis and alternative enzymatic DNA synthesis approaches SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology system

Yahoo | January 18, 2022

Read More 'DNAY' Stories Here

DNAY Price Returns

1-mo N/A
3-mo -64.25%
6-mo -82.22%
1-year -90.40%
3-year N/A
5-year N/A
YTD -82.22%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4978 seconds.